Anapharm Bioanalytics published a blog post exploring the challenges and troubleshooting strategies for developing a robust ADA assay for a small recombinant protein based on a poster presented at the 12th EBF Young Scientist Symposium.
Published
Signal category
Research & Knowledge
Quote
“Our latest blog, based on the poster presented at the 12th EBF Young Scientist Symposium, explores the key challenges encountered during assay development and the troubleshooting strategies implemented to overcome them.”
— Anapharm Bioanalytics team
Company
Anapharm Bioanalytics
We aim to become a valued partner for your product research, development and registration.
- Industry
- Research Services
- Location
- Barcelona, ES
- Company size
- 79 employees
Anapharm Bioanalytics is a customer-focused bioanalytical CRO specialized in small and large molecule bioanalysis. Led by a team with over 30 years’ experience in method development, validation and sample analysis, we support drug development programs for the pharmaceutical, biotechnological and generic industries worldwide. Equipped with state-of-the-art LC-MS/MS and LBA technology platforms, Anapharm Bioanalytics provides an array of services including PK studies, biomarker testing and immunogenicity assays throughout preclinical and clinical stages. Our global network of partners allows us to provide full-service outsourcing solutions to conduct preclinical, Phase I-IV clinical trials, and bioequivalence studies for international registration. Our clients benefit from a deep scientific expertise combined with a robust quality system. All our activities are compliant with GLP and GCP, having undergone 20+ regulatory inspections by the FDA, several EU Health Authorities and ANVISA (Brazil). Whether your drug candidate is a new chemical entity, a new biologic, a generic or a biosimilar, do not hesitate to contact us at info@anapharmbioanalytics.com.
Founded 2003